Last reviewed · How we verify
NCT04996615
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
trial testing no intervention in Breast Cancer in 5,000 participants. Status unknown.
30 September 2025
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 September 2021 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 2 locations across China |
Drugs / interventions tested
- no intervention
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Magnetic Resonance Imaging — all drugs for Magnetic Resonance Imaging →
Sponsor
Peking University People's Hospital
Who can join
Eligibility, female only, with Breast Cancer or Magnetic Resonance Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Use Convolutional Neural Networks Analysis for Classification of Contrast-enhancing Lesions at Multiparametric Breast MRI. Build an abbreviated protocal, and investigate whether an abbreviated protocol was suitable for breast magnetic resonance imaging screening for breast cancer in high-risk Chinese women, which can shorten the examination time and avoid enhanced imaging while ensuring the accuracy of the diagnosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.
Jiang B, Bao L, He S, Chen X, et al · · 2024 · cited 36× · PMID 39304962 · DOI 10.1186/s13058-024-01895-6 -
AI-driven diffusion weighted imaging-based non-contrast protocol for breast cancer diagnosis: a multicentre, multidimensional validation study.
Liu Y, Chen H, Zhao J, Wang L, et al · · 2025 · PMID 41497515 · DOI 10.1016/j.eclinm.2025.103694
Verify or expand the search:
- PubMed search for NCT04996615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of no intervention
Trials testing the same drug.
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
- NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
- NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
- NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04996615 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 16 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04996615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing